Free Trial

Zymeworks (ZYME) to Release Quarterly Earnings on Thursday

Zymeworks logo with Medical background

Zymeworks (NYSE:ZYME - Get Free Report) will likely be announcing its earnings results after the market closes on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $20.65 million for the quarter.

Zymeworks Stock Down 8.6 %

Shares of Zymeworks stock traded down $1.11 on Tuesday, hitting $11.74. The stock had a trading volume of 546,665 shares, compared to its average volume of 609,491. The stock has a market cap of $816.83 million, a price-to-earnings ratio of -7.83 and a beta of 1.24. Zymeworks has a twelve month low of $8.21 and a twelve month high of $17.70. The business's 50 day moving average is $11.95 and its two-hundred day moving average is $13.48.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Citigroup lifted their target price on Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, March 7th. Lifesci Capital initiated coverage on shares of Zymeworks in a report on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 price objective for the company. Finally, HC Wainwright raised their target price on shares of Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Monday, March 10th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $21.00.

Get Our Latest Analysis on Zymeworks

Insider Activity at Zymeworks

In related news, Director Ecor1 Capital, Llc bought 468,356 shares of the business's stock in a transaction on Thursday, March 13th. The shares were purchased at an average cost of $12.48 per share, with a total value of $5,845,082.88. Following the acquisition, the director now owns 16,802,141 shares of the company's stock, valued at $209,690,719.68. This represents a 2.87 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders acquired a total of 1,350,347 shares of company stock worth $16,137,499 in the last quarter. 1.92% of the stock is owned by insiders.

About Zymeworks

(Get Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

Featured Stories

Earnings History for Zymeworks (NYSE:ZYME)

Should You Invest $1,000 in Zymeworks Right Now?

Before you consider Zymeworks, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.

While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines